Rapport Therapeutics, Inc. (RAPP) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 1:20 PM EDT
Company Participants
Abraham Ceesay – CEO, President, Treasurer & Director
Troy Ignelzi – Chief Financial Officer
Conference Call Participants
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Presentation
Salveen Richter
Goldman Sachs Group, Inc., Research Division
Good afternoon, everyone. Thank you so much for joining us. Really pleased to have with us the Rapport team. With me, I have Abe Ceesay, Chief Executive Officer; and Troy Ignelzi, Chief Financial Officer.
To start here, Abe, Rapport is about to initiate its first pivotal program following positive proof-of-concept data in focal onset epilepsy. In this context, can you lay out the company’s key priorities and catalysts over the next 12 to 18 months?
Question-and-Answer Session
Abraham Ceesay
CEO, President, Treasurer & Director
Sure. So thank you, Salveen, for having us here today. So as a reminder, we released our Phase II data in September of ’25, and it was phenomenal data. We are very encouraged by that data with RAP-219 in focal onset seizures. That data was really marked by what we saw was pretty much unprecedented results in terms of seizure reduction, roughly a 78% median reduction in seizure frequency. That data puts us in a great position where we’re now actively enrolling our Phase III studies. So we’re able to really accelerate the start of those studies.
In addition to that, we are currently wrapping up our Phase II study in bipolar mania also with RAP-219, and we have brought-in the guidance for the readout of that trial from the first half of ’27 into the fourth quarter of this year. And then as we think about really furthering kind of the clinical utility of RAP-219, we’re also moving forward into primary generalized tonic-clonic seizures, which is
